Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox + MR-HIFU in Relapsed/Refractory Solid Tumors
NCT04791228Phase 2Withdrawn
- Sponsor
- Children's National Research Institute
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in solid tumor, sponsored by Children's National Research Institute. Primary endpoints: Response of treated target lesion(s) and Number of participants with treatment-related adverse events. Planned start Nov 2022; status: withdrawn.
02
Drugs
doxorubicin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04791228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791228.